Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development

Nature Reviews Drug Discovery

Volumn 15, Issue 3, 2016, Pages 152-

  Shea, Michael ^a   Ostermann, Linda ^a   Hohman, Ryan ^a   Roberts, Samantha ^a   Kozak, Marina ^a   Dull, Ryan ^a   Allen, Jeff ^a   Sigal, Ellen ^a  

^a Friends of Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG APPROVAL; DRUG DESIGN; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY MECHANISM; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; PROCEDURES; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84959265325     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.19     Document Type: Note

References (0)